Nanotechnology Center with profit sold its share in the project on creation of drugs for the treatment of cancer, HIV infection, and drugs necessary for organ transplants. This is the first time when innovative company, supported by the Nanotechnology Center, comes out in “independent swimming”. The project company “Nanopharma Development” was jointly created by LLC “Izvarino Pharma” and the Nanotechnology Center with the participation of international partner — the Swiss company Ferring Pharmaceuticals.
The project focuses on the development of medicines based on the use of nanoparticles — it delivers molecules of the active compound “aiming” at the right body to minimize the side effects and increase the effectiveness of drugs. The second direction is the development and production of drugs for the treatment of cancer, drugs used in transplantation and in diseases related to HIV infection.
At the moment, it has already been developed and submitted for the state registration of the drug for the treatment of leukemia “Imatinib”, as well as “Takrolimus” – the drug needed to therapy after transplantation of organs and tissues. In total, within the project there will be made up to 10 innovative drugs. There was purchased automated production line that does not require personnel contact with the drugs with the support of the Nanocenter for this project.
At the end of December 2015 the Nanocenter left the project: there was executed a deal, as a result of which the share of the center in “Nanopharma Development” was purchased by “Izvarino Pharma”. The transaction was carried out in accordance with the concluded during the stage of creation of the company in the investment agreement. As a result, the Nanocenter has duly fulfilled all obligations of the partnership and withdrew from the project with the planned yield. “Izvarino Pharma” remains the sole owner of the company “Nanopharma Development”, whose activities will continue to be carried out independently, in collaboration with the Nanocenter on a contractual basis. The issue of drugs should begin in summer 2016.
“Izvarino Pharma” and “Nanopharma Development” in the future intend to develop production and to organize in Tatarstan issue of 15 drug substances under GMP standards.
Recall that on March 26, 2010 were announced the results of the first open competition on selection of projects of nanotechnology centers creation, which was conducted by State Corporation “Rusnanotech" (JSC “RUSNANO”). The collective application of Innovative Technopark “Idea” entered into number of winners, and Technopark has received the right to conclude an investment agreement with “RUSNANO” on the implementation of the project to create the Nanotechnology Center. The company “Izvarino Pharma” has acted together with Technopark at the stage of order formation. Pharmaceutical company and Technopark “Idea” developed an anchor for the Nanotechnology Center project – “Nanopharma Development”. The Nanotechnology Center, created in the framework of the first contest of “RUSNANO”, is the union of the two legal entities. It consists of Technopark “Idea”, responsible for the infrastructure component of the project of the Nanotechnology Center (buildings and equipment) and Center for Technology Transfer (“CTT”), responsible for project activities of the Nanotechnology Center.
